skip to Main Content

R&D

Developing efficient and ultimate therapy for diseases

NP-011

Introducing NEXEL’s NP-011

NP-011 is NEXEL’s human recombinant protein, pre-clinical stage candidate with exceptional anti-fibrotic activity and safety. Its indication coverage includes all fibrotic diseases, including NASH fibrosis. NEXEL is continually seeking partners to bring the candidate successfully to commercialization.

NP-011 above 40μg/kg dramatically reduces fibrotic area in Thioacetamide (TAA)-induced liver diseased mouse.

NP-011 Pipelines

Developing Indications

Liver
(NASH-Fibrosis)

Heart
(myocardial infarction)

Lung
(fibrosis)

Back To Top